Italia markets closed

JNJ Sep 2024 125.000 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,3800-0,2300 (-37,70%)
Alla chiusura: 01:35PM EDT
Schermo intero
Chiusura precedente0,6100
Aperto0,4700
Denaro0,2900
Domanda0,5900
Prezzo d'esercizio125,00
Scadenza2024-09-20
Min-Max giorno0,3800 - 0,4700
Contratto - Min-MaxN/D
Volume7
Open Interest286
  • GlobeNewswire

    Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

    According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA